In primary breast cancer, interleukin-6 (IL-6) induced activation of its downstream effectors, JAK2 and STAT3, and this signaling played a critical and pharmacologically targetable role in orchestrating the composition of the tumor microenvironment that promotes growth, invasion, and metastasis [25]. The gene discussed is JAK2; the disease is breast carcinoma.